Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133508 | 0.84 | GRIA1 (0.41) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL31477129 | 0.84 | GRIA1 (0.41) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL2884919 | 0.83 | GRIA1 (0.56) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL5504159 | 0.82 | ALDH1A1 (0.41) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL12375394 | 0.82 | ALDH1A1 (0.41) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL15920680 | 0.81 | KDM1A (0.43) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL2435201 | 0.81 | ERN1 (0.45) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL18128766 | 0.80 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 | |
| SCHEMBL650978 | 0.80 | ERN1 (0.50) | ALDH1A1TSHRERN1KDM4ETDP1 | |
| SCHEMBL20140570 | 0.80 | ERN1 (0.40) | GRIA1GRIA2GRIA3GRIA4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-4194452-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | Shanghai Zheye Biotechnology Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3377483-B9 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-08-03 | — | — | EP | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| EP-3928836-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2021-12-29 | — | — | EP | disclosed |
| CN-108349949-B | N-substituted indole derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| US-20200251661-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-08-06 | — | — | US | disclosed |
| EP-3377483-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2018-09-26 | — | — | EP | disclosed |
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2010121995-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | GRIA1 329/4885GRIA2 426/4885GRIA3 492/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | GRIA1 329/4885GRIA2 426/4885GRIA3 492/4885 |
| US-20200251661-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | ODC1, OR10J3, CYP1A1 | GRIA1 635/4885GRIA2 1105/4885GRIA3 1691/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | GRIA1 329/4885GRIA2 426/4885GRIA3 492/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | GRIA1 3347/4885GRIA2 3213/4885GRIA3 2223/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | GRIA1 329/4885GRIA2 426/4885GRIA3 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.